World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
81
Citations
37753
World Ranking
16396
National Ranking
8250

Research.com Recognitions

  • 1958 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

David S. Siegel is affiliated with Hackensack University Medical Center in the United States. Their research primarily focuses on the fields of Medicine and Biochemistry, Genetics, and Molecular Biology, with a significant emphasis on Hematology, Molecular Biology, Oncology, Immunology, and Cancer Research.

The scientist has contributed extensively to topics such as Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, CAR-T Cell Therapy Research, Cancer Treatment and Pharmacology, Peptidase Inhibition and Analysis, Cancer Mechanisms and Therapy, and Histone Deacetylase Inhibitors Research.

Among the recent papers authored or co-authored by David S. Siegel are the following:

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma, 2021, New England Journal of Medicine
  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study, 2020, The Lancet
  • Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study, 2020, The Lancet Rheumatology
  • Targeting MCL-1 in hematologic malignancies: Rationale and progress, 2020, Blood Reviews
  • Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011), 2020, Journal of Clinical Oncology

David S. Siegel has frequently collaborated with a range of researchers, including Noa Biran, David H. Vesole, Harsh Parmar, Jesús G. Berdeja, and Sundar Jagannath.

The scientist's work is published predominantly in the following venues:

  • Blood
  • Journal of Clinical Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Transplantation and Cellular Therapy
  • Leukemia & lymphoma/Leukemia and lymphoma

David S. Siegel was recognized as a Fellow of the American Association for the Advancement of Science (AAAS) in 1958.

Best Publications

  • A phase 2 study of bortezomib in relapsed, refractory myeloma.

    Paul G. Richardson;Bart Barlogie;James Berenson;Seema Singhal

  • Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

    Noopur Raje;Jesus Berdeja;Yi Lin;David Siegel

  • Initial genome sequencing and analysis of multiple myeloma

    Michael A. Chapman;Michael S. Lawrence;Jonathan J. Keats;Kristian Cibulskis

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C Munshi;Larry D Anderson;Nina Shah;Deepu Madduri

  • Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

    Donna M. Weber;Christine Chen;Ruben Niesvizky;Michael Wang

  • Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

    S Vincent Rajkumar;Susanna Jacobus;Natalie S Callander;Rafael Fonseca

  • Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

    S. Vincent Rajkumar;Jean Luc Harousseau;Brian Durie;Kenneth C. Anderson

  • A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

    S. Jagannath;B. Barlogie;J. Berenson;D. Siegel

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani

  • A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

    David S. Siegel;Thomas Martin;Michael Wang;Ravi Vij

  • Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

    Paul G. Richardson;Hannah Briemberg;Sundar Jagannath;Patrick Y. Wen

  • Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma

    B. Barlogie;S. Jagannath;K.R. Desikan;S. Mattox

  • Toxic acute tubular necrosis following treatment with zoledronate (Zometa)

    Glen S. Markowitz;Paul L. Fine;Jay I. Stack;Cheryl L. Kunis

  • Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

    Paul G. Richardson;David S. Siegel;Ravi Vij;Craig C. Hofmeister

  • International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.

    M Dimopoulos;E Terpos;R L Comenzo;P Tosi

  • Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.

    Raman Desikan;Bart Barlogie;Bart Barlogie;Jeffrey Sawyer;Jeffrey Sawyer;Dan Ayers;Dan Ayers

  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.

    Meletios Dimopoulos;Hang Quach;Maria-Victoria Mateos;Ola Landgren

  • Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

    David Siegel;Thomas Martin;Ajay Nooka;R. Donald Harvey

  • Erratum: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (Leukemia (2012) 26 (149-157) DOI: 10.1038/leu.2011.196)

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

Frequent Co-Authors

Sagar Lonial
Sagar Lonial Emory University
Ravi Vij
Ravi Vij Washington University in St. Louis
Paul G. Richardson
Paul G. Richardson Harvard University
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Robert Z. Orlowski
Robert Z. Orlowski The University of Texas MD Anderson Cancer Center
Noopur Raje
Noopur Raje Harvard University
Nikhil C. Munshi
Nikhil C. Munshi Harvard University
Andre Goy
Andre Goy Hackensack University Medical Center
A. Keith Stewart
A. Keith Stewart Mayo Clinic
David H. Vesole
David H. Vesole Rutgers, The State University of New Jersey

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are interested in studying Medicine in the USA, there are several related degrees and alternative career pathways to consider. Many students start their healthcare journey through adn programs, which can be a more accessible route to entering the nursing field and gaining hands-on clinical experience quickly.

For those who prefer working in healthcare administration or behind-the-scenes roles, pursuing a health care administration degree online offers valuable skills for managing medical facilities, patient services, and healthcare policies.

Interested in a flexible, administrative healthcare role? You might consider accredited medical billing and coding schools online. These programs teach specialized knowledge for processing insurance claims and managing medical records, which are vital to keeping clinics and hospitals running smoothly.

Some students look for nursing programs with fewer standard entry barriers. There are nursing schools that don't require teas or HESI exams, making it easier to start a nursing career for those who may be anxious about standardized testing.

Exploring these degree options can help you find the healthcare career path that best matches your interests, schedule, and educational goals.

Best Scientists Citing David S. Siegel

Trending Scientists